Are we still putting PTAC 217 as the emperor of all biomarkers or not?

So I think, right, it's a time in the field that I think this was really shown at the meeting that I think that right now P-touch of 17 remains our best marker for kind of identifying amyloid and tau, but that there's a big interest in moving and understanding a lot of the other changes that are going on.

alongside that to the immune system, to synaptic health.

And so that's where proteomics, I think, has really started to be amplified and really had a big role at the meeting this year, where not only can we look at P-touch of 17, but we can look at how shifts in P-touch of 17 are accompanied by rises in some of these kind of immune markers beyond just what we've used in the past, things like TFAP, as well as in kind of markers of synaptic integrity.

So we have to learn a new neuropentraxin, MPTX.

It's going to be one that's going to be coming soon.

more and more, I think, into the lexicon because of its ability to kind of measure some of the more subtle changes that may be occurring early on where the neurons are dying.

What are your thoughts about our future, our actual future for predicting our brain health? What's stood out for you?